现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • MK-0812
MK-0812的可视化放大

MK-0812

A CCR2 antagonist

原价
¥2412-4175
价格
1930-3340
MK-0812的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajci7514
  • CAS: 624733-88-6
  • 别名: 1,5-酐-2,3-双脱氧-3-[[(1R,3S)-3-[[7,8-二氢-3-(三氟甲基)-1,6-萘啶-6(5H)-基]羰基]-3-(1-甲基乙基)环己基]氨基]-4-O-甲基-D-赤式-戊糖醇,MK 0812; MK0812
  • 分子式: C24H34F3N3O3
  • 分子量: 469.54
  • 纯度: >98%
  • 溶解度: DMF: 15 mg/ml,DMF:PBS (pH 7.2) (1:20): 0.04 mg/ml,DMSO: 1 mg/ml,Ethanol: 10 mg/ml
  • 储存: Store at -20°C
  • 库存: 现货

Background

MK-0812 is an antagonist of chemokine receptor CCR-2 [1].
C-C chemokine receptor type 2 (CCR-2) is a chemokine receptor expressing on monocytes and macrophages and plays a critical and apparently non-redundant role in orchestrating the trafficking of monocytes to tissues [1].
In human whole blood, MK-0812 completely blocked all MCP-1 mediated response with IC50 value of 3.2 nM in a concentration dependent way, which is similar to the inhibition of 125I-MCP-1 binding by MK-0812 on isolated monocytes (IC50 4.5 nM). Also, MK-0812 resulted in a monocyte forward scatter measurement below unstimulated or basal levels. In rhesus whole blood, MK-0812 inhibited monocyte shape change with IC50 value of 8 nM. MK-0812 inhibited monocyte recruitment in a dose-dependent way which related with the inhibition of MCP-1 induced monocyte shape change [1].
In naive BALB/c mice, MK-0812 (30 mg/kg) reduced the frequency of Ly6G-Ly6Chi monocytes in the peripheral blood. In addition, MK-0812 reduced circulating Ly6Chi monocytes and increased the CCR2 ligand CCL2 in a dose-dependent way [2].
参考文献:
[1]. Wisniewski T, Bayne E, Flanagan J, et al. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods, 2010, 352(1-2): 101-110.
[2]. Min SH, Wang Y, Gonsiorek W, et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochem Biophys Res Commun, 2010, 391(1): 1080-1086.

Protocol

Kinase experiment:

Human whole blood is collected in EDTA tubes and used within 1 h of blood collection. For antagonist treated samples, blood (200 ?L) is pre-incubated with MK-0812 (0.1% final DMSO concentration) for 30 min at room temperature. After which, 20 ?L of FITC conjugated anti-CD14 antibody and 4 ?L of chemokine or buffer is added to each sample and mixed lightly. An aliquot (100 ?L) of the blood mixture is incubated for 10 min at 37°C, immediately placed on ice and lightly fixed with 250 ?L of ice cold fixative (49 mL PBS, 1.0 mL 4% para-formaldehyde) for 1 min. Red blood cells are lysed by adding 1.0 mL of ice cold lysis solution (0.15 M NH4Cl2, 10 mM sodium bicarbonate, and 1 mM EDTA), and incubated for 20 min on ice. After complete lysis of red blood cells, 100 ?L of 4% para-formaldehyde is added and the samples are analyzed by flow cytometry for forward scatter measurements[1].

Animal experiment:

Mice[2] Female BALB/c mice are used between 8 and 10 weeks of age. SCH563705 or MK0812 are administered in a 0.4% MC solution by 30 mg/kg oral gavage (p.o.). Two hours later, the frequency of CD11b+Ly6G-Ly6Chi monocytes and CD11b+Ly6G+Ly6C+ neutrophils is determined by flow cytometry.

参考文献:

[1]. Wisniewski T, et al. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist.J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
[2]. Min SH, et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.Biochem Biophys Res Commun. 2010 Jan 1;391(1):1080-6.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服